BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mahboobnia K, Pirro M, Marini E, Grignani F, Bezsonov EE, Jamialahmadi T, Sahebkar A. PCSK9 and cancer: Rethinking the link. Biomed Pharmacother 2021;140:111758. [PMID: 34058443 DOI: 10.1016/j.biopha.2021.111758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 King RJ, Singh PK, Mehla K. The cholesterol pathway: impact on immunity and cancer. Trends in Immunology 2022;43:78-92. [DOI: 10.1016/j.it.2021.11.007] [Reference Citation Analysis]
2 Maligłówka M, Kosowski M, Hachuła M, Cyrnek M, Bułdak Ł, Basiak M, Bołdys A, Machnik G, Bułdak RJ, Okopień B. Insight into the Evolving Role of PCSK9. Metabolites 2022;12:256. [DOI: 10.3390/metabo12030256] [Reference Citation Analysis]
3 Grewal T, Buechler C. Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond. IJMS 2022;23:1070. [DOI: 10.3390/ijms23031070] [Reference Citation Analysis]
4 Pandey M, Cuddihy G, Gordon JA, Cox ME, Wasan KM. Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer. Pharmaceutics 2021;13:1509. [PMID: 34575583 DOI: 10.3390/pharmaceutics13091509] [Reference Citation Analysis]
5 Ito M, Hiwasa T, Oshima Y, Yajima S, Suzuki T, Nanami T, Sumazaki M, Shiratori F, Funahashi K, Li SY, Iwadate Y, Yamagata H, Jambaljav B, Takemoto M, Yokote K, Takizawa H, Shimada H. Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer. Front Oncol 2021;11:708039. [PMID: 34504788 DOI: 10.3389/fonc.2021.708039] [Reference Citation Analysis]